Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Myomesin-2 (MYOM2) is a large structural protein predominantly expressed in adult cardiac and fast skeletal muscle, where it localizes at the M-band of sarcomeres and provides mechanical stability essential for contraction[1][2][3][5]. It plays a key role in cross-linking thick filaments by binding to myosin, titin, and other sarcomeric proteins, forming part of the cytoskeletal scaffold that ensures the structural and metabolic integrity of muscle fibers[1][5]. MYOM2 also interacts in an isoform-specific manner with muscle-type creatine kinase, which is crucial for localized ATP generation required during muscle contraction[1]. Alterations in MYOM2 expression or structure have been implicated in various muscle and cardiovascular diseases, though it is not a conventional therapeutic target such as a receptor or enzyme[2][3][5]. Its encoded protein consists of multiple immunoglobulin-like and fibronectin type III domains. MYOM2 is essential for normal muscle function but is primarily characterized as a structural, rather than a druggable or therapeutic, molecular target.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Myomesin-2 (MYOM2).